These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34625772)

  • 1. Recreational use of GHB and prescribed drugs: the challenge in forensic and clinical toxicology.
    Brunetti P; Umani Ronchi F
    Clin Ter; 2021 Sep; 172(5):423-424. PubMed ID: 34625772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the risk of toxicity and adverse drug interactions involving recreational GHB use and prescribed drugs.
    Ricci G; Busardò FP; Gibelli F; Sirignano A; Brunetti P
    Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1445-1454. PubMed ID: 35043730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive Impairment Following Clinical or Recreational Use of Gammahydroxybutyric Acid (GHB): A Systematic Review.
    Amsterdam JV; Brunt TM; Pereira FR; Crunelle CL; Brink WVD
    Curr Neuropharmacol; 2022; 20(4):809-819. PubMed ID: 34151766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.
    Busardò FP; Jones AW
    Curr Neuropharmacol; 2015 Jan; 13(1):47-70. PubMed ID: 26074743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpreting γ-hydroxybutyrate concentrations for clinical and forensic purposes.
    Busardò FP; Jones AW
    Clin Toxicol (Phila); 2019 Mar; 57(3):149-163. PubMed ID: 30307336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) for determination of GHB, precursors and metabolites in different specimens: Application to clinical and forensic cases.
    Busardò FP; Kyriakou C; Marchei E; Pacifici R; Pedersen DS; Pichini S
    J Pharm Biomed Anal; 2017 Apr; 137():123-131. PubMed ID: 28110168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Withdrawal syndrome following chronic use of gamma-hydroxybutyric acid (GHB)].
    Moitroux A; Kestens C
    Rev Med Liege; 2023 Jul; 78(7-8):451-455. PubMed ID: 37560960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome.
    Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4654-63. PubMed ID: 26698265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma hydroxybutyric acid (GHB) intoxication.
    Mason PE; Kerns WP
    Acad Emerg Med; 2002 Jul; 9(7):730-9. PubMed ID: 12093716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management.
    Marinelli E; Beck R; Malvasi A; Lo Faro AF; Zaami S
    Arh Hig Rada Toksikol; 2020 Mar; 71(1):19-26. PubMed ID: 32597141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal.
    Miotto K; Darakjian J; Basch J; Murray S; Zogg J; Rawson R
    Am J Addict; 2001; 10(3):232-41. PubMed ID: 11579621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.
    Felmlee MA; Morse BL; Morris ME
    AAPS J; 2021 Jan; 23(1):22. PubMed ID: 33417072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.
    J Toxicol Clin Toxicol; 2003; 41(2):131-5. PubMed ID: 12733850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Xyrem risk management program.
    Fuller DE; Hornfeldt CS; Kelloway JS; Stahl PJ; Anderson TF
    Drug Saf; 2004; 27(5):293-306. PubMed ID: 15061684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome.
    Gallimberti L; Canton G; Gentile N; Ferri M; Cibin M; Ferrara SD; Fadda F; Gessa GL
    Lancet; 1989 Sep; 2(8666):787-9. PubMed ID: 2571021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
    Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
    Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence.
    Mannucci C; Pichini S; Spagnolo EV; Calapai F; Gangemi S; Navarra M; Calapai G
    Curr Drug Metab; 2018; 19(13):1056-1064. PubMed ID: 29219048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.
    Carter LP; Pardi D; Gorsline J; Griffiths RR
    Drug Alcohol Depend; 2009 Sep; 104(1-2):1-10. PubMed ID: 19493637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of N-methyl-2-pyrrolidone (NMP) and the "date rape" drug GHB: behavioral toxicology in the mouse model.
    Arfè R; Bilel S; Tirri M; Frisoni P; Serpelloni G; Neri M; Boccuto F; Bernardi T; Foti F; De-Giorgio F; Marti M
    Psychopharmacology (Berl); 2021 Aug; 238(8):2275-2295. PubMed ID: 33881584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence.
    Galloway GP; Frederick SL; Staggers FE; Gonzales M; Stalcup SA; Smith DE
    Addiction; 1997 Jan; 92(1):89-96. PubMed ID: 9060200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.